<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04565301</url>
  </required_header>
  <id_info>
    <org_study_id>MS-161-2020</org_study_id>
    <nct_id>NCT04565301</nct_id>
  </id_info>
  <brief_title>Neostigmine and Dexamethasone in Adductor Canal Block</brief_title>
  <official_title>A Comparative Study Between Neostigmine and Dexamethasone as an Adjuvant to Bupivacaine in Adductor Canal Block After Knee Arthroscopy Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare between the efficacy of neostigmine and dexamethasone as an adjuvant to&#xD;
      bupivacaine in adductor canal block after knee arthroscopy surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      90 participants in this study will be randomized into three groups based on computer&#xD;
      generated numbers using computerized generated random tables. The patients enrolled in the&#xD;
      study will be transferred to the operation room and monitored all through the surgical&#xD;
      procedure using pulse oximeter, non-invasive blood pressure and ECG.&#xD;
&#xD;
      To perform spinal anesthesia ,the patient will be positioned in the sitting position then&#xD;
      sterilization of the back using betadine solution 5% will be done then the iliac crest will&#xD;
      be identified and the opposite intervertebral space(L4-L5) will be marked then 5 ml of&#xD;
      lidocaine 2% will be infiltrated in the skin and subcutaneous tissue then a spinal needle&#xD;
      (25G) will be introduced to the intrathecal space and after ensuring that clear&#xD;
      cereÂ¬brospinal fluid will be in free flow injection of 15-20mg of bupivacaine 0.5% and 25mcg&#xD;
      of fentanyl will be administrated then the patient will be positioned in the supine position.&#xD;
&#xD;
      If hypotension, (decrease in the mean arterial blood pressure of more than 20%from base line)&#xD;
      occurs, 9mg intravenous ephedrine will be given with 200ml bolus crystalloids. If bradycardia&#xD;
      (heart rate below 50beat / minute) occurs, 0.5mg intravenous atropine will be given. After&#xD;
      the surgical procedure the patients will be randomly allocated using computerized generated&#xD;
      random tables in to three equal groups and the random numbers will be concealed in closed&#xD;
      opaque envelopes which will be kept by the senior anesthesia staff, the three groups are:&#xD;
&#xD;
        -  Group N: The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1&#xD;
           ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal&#xD;
           block.&#xD;
&#xD;
        -  Group D: The patients in this group will be administered 8 mg dexamethasone (2 ml) (23)&#xD;
           as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.&#xD;
&#xD;
        -  Group C: The patients in this group will be administered 2 ml isotonic saline + 20 ml&#xD;
           bupivacaine 0.50 % in the adductor canal block (control group).&#xD;
&#xD;
      With the patient in the supine position, the procedural needle (Braun Stimuplex Ultra&#xD;
      Insuflated Echogenic Needle 22G) will be inserted in plane from the anteromedial side at the&#xD;
      mid thigh level. It will be advanced through the sartorius muscle and fascia under ultrasound&#xD;
      guidance, using a Siemens Acuson X300 ultrasound equipped with a linear transducer after&#xD;
      sterilization of the skin with betadine solution 5%, and the adductor canal, with the&#xD;
      superficial femoral artery and vein within, will be identified. Once the needle tip will be&#xD;
      located in the adductor canal, the anaesthetic solution will be injected anterior to the&#xD;
      artery and deep into the sartorius muscle (24) then patient will be transferred to the PACU&#xD;
      then to the ward.&#xD;
&#xD;
      Postoperative&#xD;
&#xD;
        1. Postoperative pain will be assessed by visual analog scale (VAS)&#xD;
&#xD;
        2. A fixed dose of intravenous paracetamol 1 gram will be given every 6 hours to all&#xD;
           patients in the three groups starting from 1 hour after the ACB.&#xD;
&#xD;
        3. Postoperative pain assessment through VAS will be according to the scale as follow:&#xD;
&#xD;
             -  Pain level 0: no pain&#xD;
&#xD;
             -  Pain level1-3: mild pain&#xD;
&#xD;
             -  Pain level 4-6: moderate pain&#xD;
&#xD;
             -  Pain level 7-10: severe pain&#xD;
&#xD;
        4. Postoperative pain will be managed as follow:&#xD;
&#xD;
             -  Mild pain will be treated with ketolac 30mg IV.&#xD;
&#xD;
             -  Moderate pain will be treated with ketolac 30mg IV + morphine 0.07mg/kg IV.&#xD;
&#xD;
             -  Severe pain will be treated with ketolac 30mg IV &amp; morphine 0.1mg/kg IV. Then&#xD;
                patient will be reassessed and recorded as mentioned above and the specific&#xD;
                treatment will be repeated after 8 hours from the initial dose according to VAS.&#xD;
&#xD;
        5. Opioids complications such as respiratory depression will be recorded and managed&#xD;
           supportively by oxygen mask, controlled airway and if persistent or severe&#xD;
           hypoventilation occurs positive pressure ventilation may be needed, nausea and vomiting&#xD;
           will be treated with ondansterone (4mg IV).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>first rescue analgesia time</measure>
    <time_frame>24 hours</time_frame>
    <description>Time (in hours) of first rescue analgesia (morphine) requirement for each group in the first 24 hours following the adductor canal block</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morphine consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Total amount of morphine consumed in the first 24 hours following the AC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analogue scale</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>VAS score at times 0-30 minutes, 1, 2, 4, 8, 12, 18 and 24 hours postoperatively. As visual analouge scale (VAS) is a scale from 0 to 10 where &quot;0&quot; means no pain and &quot;10&quot; means the most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sensory block</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>Duration of sensory block at times 0-30 minutes, 1, 2, 4, 8, 12, 18 and 24 hours postoperatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of Nausea and vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>through a question answered by yes or no to identify the presence of nausea and vomiting</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients in this group will be administered 2 ml isotonic saline + 20 ml bupivacaine 0.50 % in the adductor canal block (control group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this group will be administered 8 mg dexamethasone (2 ml) (23) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group N</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients in this group will be administered 500 mcg neostigmine (1 ml) + 1 ml isotonic saline (22) as adjuvant to 20 ml bupivacaine 0.50 % in the adductor canal block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>adductor canal block</description>
    <arm_group_label>Group D</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neostigmine</intervention_name>
    <description>adductor canal block</description>
    <arm_group_label>Group N</arm_group_label>
    <other_name>prostigmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NaCl solutions</intervention_name>
    <description>adductor canal block</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients undergoing knee arthroscopy surgery.&#xD;
&#xD;
          -  Age between 18 years and 65 years.&#xD;
&#xD;
          -  Both sexes&#xD;
&#xD;
          -  ASA I &amp; ASA II&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients' refusal&#xD;
&#xD;
          -  Allergy to any drug that will be used in the study&#xD;
&#xD;
          -  Psychological or mental disorders.&#xD;
&#xD;
          -  Disturbance of Conscious level.&#xD;
&#xD;
          -  Uncooperative patients&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Contraindications to spinal anaesthesia (e.g.: severe mitral stenosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Heba Omar Ahmed Omar</name>
      <address>
        <city>Giza</city>
        <state>Haram</state>
        <zip>12562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heba Om Omar, Md</last_name>
      <phone>+201128102222</phone>
      <email>hebaomar2@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2020</study_first_posted>
  <last_update_submitted>June 19, 2021</last_update_submitted>
  <last_update_submitted_qc>June 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Heba Omar Ahmed</investigator_full_name>
    <investigator_title>Associate professor of Anesthesia, pain management &amp; surgical ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

